ArticlePLoS neglected tropical diseases2025
Schistosoma japonicum cathepsin L1: A potential target for anti-schistosomiasis strategies.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correction: Schistosoma japonicum cathepsin L1: A potential target for anti-schistosomiasis strategies.PLoS neglected tropical diseases · 2025Article
- From cercariae to chronic inflammation: understanding schistosome infection and host immune responses.Frontiers in immunology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
backgroundTo achieve sustainable and integrated control of schistosomiasis, it necessitates the implementation of comprehensive strategies, where effective vaccines could play a pivotal role. The limited identification and validation of schistosome antigens hinders the progress of vaccine development for the disease. Schistosome cysteine proteinases are considered as important targets for novel anti-schistosomiasis immunoprophylaxis due to their primary role in nutrient absorption. Previous research on the Schistosoma japonicum degradome has identified a group of cathepsin L-like proteases (SjCLs) that are up-regulated in hepatic schistosomula and adult worms. METHODS/
findingsIn this study, five recombinant proteins representing the mature form of these SjCLs, designated as rSjCL1-5, were successfully produced. Mice immunized with the rSjCLs were subsequently challenged with cercariae to evaluate the immunoprotective efficacy of these proteins. The expression and localization of SjCL1 were analyzed by qRT-PCR, western blotting and immunofluorescence assays. Among these five rSjCLs, only the immunization with rSjCL1 conferred partial protection to the mice against S. japonicum infection, resulting in a reduction in worm burden by 34.9% ~ 38.0% and a decrease of egg burden by 46.2% ~ 48.3%. This immunization also effectively mitigated body weight loss and hepatomegaly in the challenged mice. SjCL1 was primarily localized along the intestinal intima of hepatic schistosomula, as well as male and female adults, and on the tegument of male adults. The mature form of SjCL1 was detected in the excretory/secretory products of the parasites. Hepatic schistosomulum treated with SjCL1 antibodies in vitro showed significant growth retardation, although remained viable and developed intestinal heme pigmentation, indicative of hemoglobin digestion. CONCLUSIONS/SIGNIFICANCE: Our study revealed that SjCL1 is essential for normal parasite growth and shed new light for the development of schistosomiasis vaccines targeting cathepsins, which play a key role in the early intra-mammalian stages of schistosomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.